JP2008528542A - ロスバスタチンカルシウム塩の結晶形 - Google Patents

ロスバスタチンカルシウム塩の結晶形 Download PDF

Info

Publication number
JP2008528542A
JP2008528542A JP2007552625A JP2007552625A JP2008528542A JP 2008528542 A JP2008528542 A JP 2008528542A JP 2007552625 A JP2007552625 A JP 2007552625A JP 2007552625 A JP2007552625 A JP 2007552625A JP 2008528542 A JP2008528542 A JP 2008528542A
Authority
JP
Japan
Prior art keywords
methyl
fluorophenyl
isopropyl
methylsulfonyl
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007552625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008528542A5 (enExample
Inventor
ブラッター，フリッツ
ファン・デル・スハーフ，パウル・アドリアーン
シェラギエヴィッツ，マルティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Schweiz AG
Original Assignee
Ciba Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Holding AG filed Critical Ciba Holding AG
Publication of JP2008528542A publication Critical patent/JP2008528542A/ja
Publication of JP2008528542A5 publication Critical patent/JP2008528542A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007552625A 2005-01-31 2006-01-23 ロスバスタチンカルシウム塩の結晶形 Pending JP2008528542A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05100598 2005-01-31
PCT/EP2006/050351 WO2006079611A1 (en) 2005-01-31 2006-01-23 Crystalline forms of rosuvastatin calcium salt

Publications (2)

Publication Number Publication Date
JP2008528542A true JP2008528542A (ja) 2008-07-31
JP2008528542A5 JP2008528542A5 (enExample) 2009-03-26

Family

ID=36168368

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007552625A Pending JP2008528542A (ja) 2005-01-31 2006-01-23 ロスバスタチンカルシウム塩の結晶形

Country Status (5)

Country Link
US (1) US7932387B2 (enExample)
EP (1) EP1844021A1 (enExample)
JP (1) JP2008528542A (enExample)
CA (1) CA2594692A1 (enExample)
WO (1) WO2006079611A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014050874A1 (ja) * 2012-09-27 2014-04-03 東和薬品株式会社 ロスバスタチンカルシウムの新規結晶形態およびその製造方法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
EP1562912A2 (en) 2003-08-28 2005-08-17 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
TW200526596A (en) 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
CA2546894C (en) 2003-12-02 2009-09-08 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
JP2008526781A (ja) 2005-02-22 2008-07-24 テバ ファーマシューティカル インダストリーズ リミティド ロスバスタチンの製造
KR20070062996A (ko) 2005-08-16 2007-06-18 테바 파마슈티컬 인더스트리즈 리미티드 결정성 로수바스타틴 중간체
WO2007125547A2 (en) 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Novel process for statins and its pharmaceutically acceptable salts thereof
WO2008036286A1 (en) 2006-09-18 2008-03-27 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin calcium
SI2086945T1 (sl) 2006-10-09 2016-05-31 Msn Laboratories Private Limited Novi postopek za pripravo statinov in njihovih farmacevtsko sprejemljivih soli
CA2725052C (en) 2008-05-27 2014-09-16 Changzhou Pharmaceutical Factory Co., Ltd. Preparation method of rosuvastatin calcium and its intermediates
SI2373609T1 (sl) * 2008-12-19 2013-12-31 Krka, D.D., Novo Mesto Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
EP2327682A1 (en) * 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
SI2752407T1 (sl) * 2009-01-14 2016-07-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalni kalcijev rosuvastatin trihidrat
WO2010089770A2 (en) 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
HUP0900285A2 (en) 2009-05-07 2011-01-28 Egis Gyogyszergyar Nyilvanosan Mukoedoe Reszvenytarsasag Rosuvastatin salts and preparation thereof
WO2011018185A2 (en) * 2009-08-13 2011-02-17 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
WO2011074016A1 (en) * 2009-12-17 2011-06-23 Matrix Laboratories Ltd Novel polymorphic forms of rosuvastatin calcium and process for preparation of the same
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
HU230737B1 (hu) 2010-11-16 2018-01-29 EGIS Gyógyszergyár Nyrt Eljárás rosuvastatin só előállítására
WO2012069394A1 (en) 2010-11-22 2012-05-31 Basf Se Multicomponent system of rosuvastatin calcium salt and sorbitol
DE202012011888U1 (de) * 2011-04-18 2013-03-21 Basf Se Kristallines Mehrkomponentensystem von Rosuvastatin-Calciumsalz und Vanillin
WO2017183040A1 (en) 2016-04-18 2017-10-26 Morepen Laboratories Limited New polymorphic form of crystalline rosuvastatin calcium & novel processes for crystalline as well as amorphous rosuvastatin calcium
CN105837516B (zh) * 2016-05-16 2018-07-10 山东新时代药业有限公司 一种瑞舒伐他汀钙晶型及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002539078A (ja) * 1999-01-09 2002-11-19 アストラゼネカ アクチボラグ 結晶質の化合物ビス［（ｅ）−７−［４−（４−フルオロフェニル）−６−イソプロピル−２−［メチル（メチルスルホニル）アミノ］ピリミジン−５−イル］（３ｒ，５ｓ）−３，５−ジヒドロキシ−６−ヘプテン酸］カルシウム塩

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
EP3299359A1 (en) * 2003-02-12 2018-03-28 Nissan Chemical Industries, Ltd. Crystalline and amorphous forms of pitavastatin hemicalcium salt
WO2005037787A1 (en) * 2003-10-16 2005-04-28 Ciba Specialty Chemicals Holding Inc. Crystalline form of fluvastatin sodium
EP1709008A1 (en) 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
WO2005075467A2 (en) * 2004-02-06 2005-08-18 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
US20080234302A1 (en) 2004-09-27 2008-09-25 Mohammad Rafeeq Novel Processes for Preparing Amorphous Rosuvastatin Calcium and a Novel Polymorphic Form of Rosuvastatin Sodium
WO2008036286A1 (en) * 2006-09-18 2008-03-27 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin calcium

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002539078A (ja) * 1999-01-09 2002-11-19 アストラゼネカ アクチボラグ 結晶質の化合物ビス［（ｅ）−７−［４−（４−フルオロフェニル）−６−イソプロピル−２−［メチル（メチルスルホニル）アミノ］ピリミジン−５−イル］（３ｒ，５ｓ）−３，５−ジヒドロキシ−６−ヘプテン酸］カルシウム塩

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014050874A1 (ja) * 2012-09-27 2014-04-03 東和薬品株式会社 ロスバスタチンカルシウムの新規結晶形態およびその製造方法

Also Published As

Publication number Publication date
US20080194604A1 (en) 2008-08-14
EP1844021A1 (en) 2007-10-17
US7932387B2 (en) 2011-04-26
WO2006079611A1 (en) 2006-08-03
CA2594692A1 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
JP2008528542A (ja) ロスバスタチンカルシウム塩の結晶形
EP1678139B1 (en) Solid-state montelukast
EP2909191B1 (en) Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
CN111225665A (zh) 大环免疫调节剂
JP2012517456A (ja) 新規なシタグリプチンの塩
EP2864313A1 (en) Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
JP2008543976A (ja) ペメトレキセド二酸の医薬上許容される凍結乾燥塩の調製方法
EP2631234A1 (en) Solid forms of dabigatran etexilate mesylate and processes for their preparation
JP2018520188A (ja) 呼吸器合胞体ウイルス（ｒｓｖ）感染症の処置のためのｎ−［（３−アミノ−３−オキセタニル）メチル］−２−（２，３−ジヒドロ−１，１−ジオキシド−１，４−ベンゾチアゼピン−４（５ｈ）−イル）−６−メチル−４−キナゾリンアミンの結晶形
CN102471273B (zh) 2-[[[2-[(羟基乙酰基)氨基]-4-吡啶基]甲基]硫代]-n-[4-(三氟甲氧基)苯基]-3-吡啶甲酰胺苯磺酸盐、其晶体、其多晶型物以及用于制备其的方法
JP2022530546A (ja) カスパーゼ阻害剤のプロドラッグ
US9249108B2 (en) Multicomponent system of rosuvastatin calcium salt and sorbitol
JP2007525538A (ja) バラシクロビル塩酸塩の結晶フォーム（ｆｏｒｍ）
WO2019102492A1 (en) Crystalline polymorphs of abemaciclib
US20060293377A1 (en) Amorphous and polymorphic forms of telmisartan sodium
JP2022505033A (ja) ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
EP4658637A1 (en) Solid forms, salts and polymorphs of anti-fibrotic compounds
JP2009536638A (ja) アトルバスタチンマグネシウムの結晶性形状ｂ４及びその方法
HUP0103947A2 (hu) Egy piridopirazinszármazék metán-szulfonát sója és annak kristályai és ezek gyógyászati alkalmazása
JP2007537206A (ja) ピリジニルスルホンアミドの結晶質形態、およびエンドセリン受容体アンタゴニストとしてのその使用
JP2001507711A (ja) テトラゾリルベンゾピランの製法
EP2610239A1 (en) Preparation Of Rasagiline Hemitartrate
JPH083162A (ja) イミダゾピリジン誘導体及びその製法
KR20060126985A (ko) (+)- 및 (-)-에리트로-메플로퀸 히드로클로라이드의 결정형
CN105073713A (zh) 药学上可接受的匹伐他汀胺盐

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120409

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130326

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130827